Pituitary stalk interruption syndrome biomarker as well as determination method and application thereof

A biomarker and determination method technology, applied in the field of pituitary stalk blockage syndrome biomarkers and its determination, can solve the problems of difficult operation, difficult diagnosis, expensive MRI diagnosis, etc., and achieve easy operation, low cost and fast The effect of batch detection

CN113834889APending Publication Date: 2021-12-24PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-12-24

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a pituitary stalk interruption syndrome biomarker, which is selected from one or more of pregnenolone sulfate, L-saccharin, MG(18:2(9Z,12Z) / 0:0 / 0:0), heneicosanoic acid, glyceryl monostearate, hydroxyphenyllactic acid, D-Lyxose, inositol, D-aspartic acid and PA(18:1_22:6). The invention further provides a determination method of the marker and application of the marker in preparation of a kit and / or a reagent for diagnosing pituitary stalk interruption syndrome. The invention creatively provides a concept of diagnosing the pituitary stalk interruption syndrome through using the biomarker, provides the pituitary stalk interruption syndrome biomarker and the specific determination method and application thereof, provides more choices and supports for diagnosis and research of the pituitary stalk interruption syndrome, is low in cost and easy to operate, and can carry out rapid batch detection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the related field of biological identification, in particular, it relates to a biomarker of pituitary stalk interruption syndrome and its determination method and application. Background technique

[0002] Pituitary stalk interruption syndrome (pituitary stalk interruption syndrome, PSIS) is the absence or thinning of the pituitary stalk, which causes the hormones secreted by the hypothalamus to be unable to be transported to the posterior pituitary through the pituitary stalk, and unable to act on the anterior pituitary through the pituitary portal system. resulting clinical syndrome. There are varying degrees of pituitary hormone deficiency in PSIS patients. Growth retardation and lack of puberty are the main clinical manifestations. Early detection, early diagnosis, and early treatment are crucial to improving the symptoms of hormone deficiency in patients, especially the development of height and gonads; if the timing of ...

Examples

Embodiment 1

[0030] The present embodiment provides PSIS diagnostic biomarkers, the biomarkers are pregnenolone sulfate and L-

[0031] saccharin.

[0032] 21 PSIS patients (BD group), 23 nCHH patients (HH group), 20 varicocele patients (VC group) and 23 healthy controls with normal semen parameters (HC group) were recruited from Peking Union Medical College Hospital. Diagnostic criteria include: (a) growth hormone deficiency; (b) triad of absent or thin pituitary stalk, pituitary hypoplasia, and / or ectopic neurohypophysis on magnetic resonance imaging (MRI). All patients and HCs included were of Han nationality. Semen samples were generated by masturbation after ≥3 days of abstinence. The basic information of all participants is listed in Table 1.

[0033] All PSIS patients had abnormalities (100%). Their mean age was 24.6±4.9 years. Many patients had non-liquefied semen (10 / 21) and concentrated semen (9 / 21). PSIS patients had smaller testicular volume (PSIS group 5.9±2.6ml vs HC gr...

Embodiment 2

[0056] Different from Example 1, BD vs nCHH, according to the main difference lipid species, combined with multi-stage mass spectrometry information to search the metabolite database, can preliminarily determine that the PSIS biomarker can also be MG (18:2(9Z, 12Z) / 0:0 / 0:0). Validated by ROC, PSIS can be distinguished from other types of male infertility patients. The marker can be used to prepare a PSIS diagnostic kit and / or reagent.

Embodiment 3

[0058] Different from Example 1, BD vs VC, according to the main differential lipid species, combined with multi-stage mass spectrometry information to search the metabolite database, it can be preliminarily determined that the PSIS biomarker can also be uncosanoic acid. Validated by ROC, PSIS can be distinguished from other types of male infertility patients. The marker can be used to prepare a PSIS diagnostic kit and / or reagent.